Editas Medicine (EDIT) Shares Outstanding (Diluted Average) (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $85.9 million in Q3 2025.

• Shares Outstanding (Diluted Average) for Q3 2025 came in at $85.9 million, up 4.42% year-over-year; the trailing twelve-month figure through Sep 2025 was $85.9 million (up 4.42% YoY), and the FY2024 annual result was $82.3 million, up 8.39% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $85.9 million in Q3 2025 per EDIT's latest filing, from $83.7 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $85.9 million in Q3 2025 and troughed at $66.0 million in Q1 2021.
• A 5-year average of $74.5 million and a median of $71.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) increased 0.59% in 2022, then climbed 18.88% in 2024.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $67.6 million in 2021, then grew by 1.55% to $68.7 million in 2022, then grew by 10.63% to $76.0 million in 2023, then gained by 8.39% to $82.3 million in 2024, then climbed by 4.3% to $85.9 million in 2025.
• Business Quant data shows EDIT's Shares Outstanding (Diluted Average) at $85.9 million in Q3 2025, $83.7 million in Q2 2025, and $83.1 million in Q1 2025.